safety and tolerability
Showing 1 - 18 of 18
Safety and Tolerability Trial in Shanghai (JMKX003142 will be administered orally, Placebo in Cohorts 1 to 7, Placebo in 3
Recruiting
- Safety and Tolerability
- JMKX003142 will be administered orally
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Oct 13, 2023
Safety and Tolerability Trial in Neuss (ZP7570, Placebo)
Not yet recruiting
- Safety and Tolerability
- ZP7570
- Placebo
-
Neuss, North Rhine-Westphalia, GermanyProfil Institut für Stoffwechselforschung GmbH
Aug 18, 2023
Healthy, Safety and Tolerability Trial in Cypress (DF-003, Placebo)
Recruiting
- Healthy
- Safety and Tolerability
- DF-003
- Placebo
-
Cypress, CaliforniaAltasciences Clinical Los Angeles, Inc
Aug 9, 2023
Safety and Tolerability Trial in Shanghai (JMKX003002 will be administered orally, Placebo in Cohorts 1 to 5, Placebo in 2
Recruiting
- Safety and Tolerability
- JMKX003002 will be administered orally
- +2 more
-
Shanghai, Shanghai, ChinaHuashan Hospital Fudan University
Jun 15, 2023
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)
Active, not recruiting
- Advanced Solid Malignancy
- +13 more
-
Los Angeles, California
- +33 more
Dec 22, 2022
Healthy Adult Subjects, Pharmacokinetics, Safety and Tolerability Trial in Baltimore (Low dose KT07, High dose KT07, Low dose
Completed
- Healthy Adult Subjects
- +2 more
- Low dose KT07
- +3 more
-
Baltimore, MarylandPharmaron
Oct 13, 2022
Safety and Tolerability Trial in Baltimore (YJ001 for Spray Use, Placebo of YJ001 for Spray Use)
Not yet recruiting
- Safety and Tolerability
- YJ001 for Spray Use
- Placebo of YJ001 for Spray Use
-
Baltimore, MarylandPharmaron CPC, Inc.
Jul 5, 2022
Safety and Tolerability Trial in Glendale (Experimental drug: ESK-001, Placebo)
Recruiting
- Safety and Tolerability
- Experimental drug: ESK-001
- Placebo
-
Glendale, CaliforniaAlumis Central site
Jun 20, 2022
Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)
Completed
- Hepatitis
- Safety and Tolerability
- HEPLISAV-B
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 13, 2022
Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI
Active, not recruiting
- Safety and Tolerability
- +3 more
- Zoster Vaccine Recombinant, Adjuvanted
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 10, 2022
Safety and Tolerability Trial in Leeds (GB1211, Placebo)
Completed
- Safety and Tolerability
- GB1211
- Placebo
-
Leeds, United Kingdom(For Parts A and B) Covance Clinical Research Unit Ltd
Feb 25, 2021
Safety and Tolerability Trial in Turku (GT-002, Placebo oral capsule)
Completed
- Safety and Tolerability
- GT-002
- Placebo oral capsule
-
Turku, FinlandCRST Oy, Clinical Research Services Turku
Feb 4, 2020
Safety and Tolerability Trial in Cypress (inhaled human insulin, Insulin Lispro (Humalog U-100))
Terminated
- Safety and Tolerability
- inhaled human insulin
- Insulin Lispro (Humalog U-100)
-
Cypress, CaliforniaWCCT
Sep 11, 2019
Safety and Tolerability Trial in Miami (Sevuparin)
Completed
- Safety and Tolerability
-
Miami, FloridaClinical Pharmacology of Miami (CPMI)
Jul 15, 2019
Safety and Tolerability Trial in Leeds (DP13, )
Completed
- Safety and Tolerability
- DP13
- placebo
-
Leeds, United KingdomCovance Clinical Research Unit Ltd
Apr 13, 2018
Safety and Tolerability Trial in Phoenix (Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days)
Completed
- Safety and Tolerability
- Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
-
Phoenix, ArizonaPulmonary Associates, PA
Feb 17, 2017
Safety and Tolerability Trial in London (ACT-128800, Placebo)
Completed
- Safety and Tolerability
- ACT-128800
- Placebo
-
London, United KingdomQuintiles Drug Research Unit at Guy's Hospital
Jan 6, 2014